New drug duo takes on stubborn hodgkin lymphoma

NCT ID NCT05723055

Ongoing Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two drugs—nivolumab and axatilimab—can help people with classical Hodgkin lymphoma that has come back or not responded to prior treatments. The study includes 9 adults who have already tried at least one other therapy. Researchers will measure how many patients respond and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and axatilimab (two antibody drugs given together)
What this could lead to: If it works, this could offer a new treatment option for people with Hodgkin lymphoma that hasn't responded to other therapies.
What could go wrong: This is a very small, early-phase trial with only 9 participants, so results may not apply widely. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, 84112, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.